Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Chupp

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
The New England Journal of Medicine|May 12, 2021
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaAndrew Menzies-Gow, Jonathan Corren, Arnaud Bourdin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 26, 2022
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe AsthmaCharles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, et al.
Allergy|October 3, 2024
Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophilsKathleen M Buchheit, Dominick Shaw, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
The European Respiratory Journal|May 7, 2021
SPLUNC1: a novel marker of cystic fibrosis exacerbationsSara Khanal, Megan Webster, Naiqian Niu, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patientsPhilip E Silkoff, Michel Laviolette, Dave Singh, et al.
Chest|May 9, 2021
ResponseChristina C Price, Frederick L Altice, Marwan M Azar, et al.
American Journal of Respiratory and Critical Care Medicine|April 4, 2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical TrialsJonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, et al.
The Journal of Experimental Medicine|May 6, 2009
Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosisChun Geun Lee, Dominik Hartl, Gap Ryol Lee, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
American Journal of Respiratory and Critical Care Medicine|February 25, 2026
Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: A multicenter, randomized, double-blind, Phase 3A Clinical Trial (NIMBLE)Geoffrey Chupp, Hiroyuki Nagase, Dirk Skowasch, et al.
The New England Journal of Medicine|May 12, 2021
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaAndrew Menzies-Gow, Jonathan Corren, Arnaud Bourdin, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 26, 2022
REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe AsthmaCharles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, et al.
Allergy|October 3, 2024
Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophilsKathleen M Buchheit, Dominick Shaw, Geoffrey Chupp, et al.
The Lancet. Respiratory Medicine|January 26, 2023
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension studyAndrew Menzies-Gow, Michael E Wechsler, Christopher E Brightling, et al.
The European Respiratory Journal|May 7, 2021
SPLUNC1: a novel marker of cystic fibrosis exacerbationsSara Khanal, Megan Webster, Naiqian Niu, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2017
Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patientsPhilip E Silkoff, Michel Laviolette, Dave Singh, et al.
Chest|May 9, 2021
ResponseChristina C Price, Frederick L Altice, Marwan M Azar, et al.
American Journal of Respiratory and Critical Care Medicine|April 4, 2023
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical TrialsJonathan Corren, Andrew Menzies-Gow, Geoffrey Chupp, et al.
The Journal of Experimental Medicine|May 6, 2009
Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosisChun Geun Lee, Dominik Hartl, Gap Ryol Lee, et al.
Pageof 6